Metavia presents preclinical data on DA-1241 showing additive protection effects in combination with efxifermin at the ADA’s 85th scientific session

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.